**SSA01**

**Breast Imaging (Multimodality Screening and Breast Density)**

Sunday, Nov. 26 10:45AM - 12:15PM Room: Arie Crown Theater

**Participants**
Colleen H. Neal, MD, Ann Arbor, MI (Moderator) Nothing to Disclose
Liane E. Philpotts, MD, New Haven, CT (Moderator) Consultant, Hologic, Inc

**Sub-Events**

**SSA01-01** Discordant Interpretation of Screen-Detected Cancers Using Tomosynthesis and Independent Double Reading in a Population-Based Mammography Screening Program

Sunday, Nov. 26 10:45AM - 10:55AM Room: Arie Crown Theater

**Participants**
Per Skaane, MD, PhD, Oslo, Norway (Presenter) Equipment support, Hologic, Inc Consultant, Hologic, Inc Support, Hologic, Inc
Randi Gullien, RT, Oslo, Norway (Abstract Co-Author) Support, Hologic, Inc; Travel support, Hologic, Inc
Bjorn Helge Osteras, MSc, Oslo, Norway (Abstract Co-Author) Nothing to Disclose

**For information about this presentation, contact:**
PERSKA@ous-hf.no

**PURPOSE**
Analyze missed screening cancers (SDC) with tomosynthesis (DBT) using independent double reading in population-based screening

**METHOD AND MATERIALS**
Trial was approved by Ethical Committee. Participating women signed a written consent. 24,301 women age 50-69 undergoing FFDM+DBT were included. The trial had 4 arms A-D: A=FFDM, B=FFDM+CAD, C=FFDM+DBT, D=syn2D+DBT. Reading was performed in batch mode using a 5-point rating scale. 8 readers participated alternating between reading modes. Scores 1 (neg) and 2-5 (pos) were stored directly into the national screening database. Cases with positive score by at least one reader were discussed at arbitration meeting before final decision for recall. There was automated recording of all reading times directly into the screening database. For purpose of this analysis, mainly the two arms C-D including DBT were analyzed.

**RESULTS**
230 SDC were diagnosed: 3 cancers in arm A+B only, 172 cancers in both main arms A+B and C+D, and 55 cancers in arm C+D only (detection rate 2D=175 or 7.2/1000 vs. 2D+3D=227 or 9.3/1000, p<0.001). Among SDC in both main arms, discordant rate (cancer missed by one reader) was 50/172 (29%) for arms A-B and 41/172 (24%) for arms C-D. Discordant rate for DBT-only was 30/55 (55%). Discordant cancers for arms C-D among the 172 SDC included spiculated mass or distortion in 17/41 (41%) and in 21/30 (70%) for DBT-only cases. Discordance for microcalc's only was 16/41 (39%) and 2/30 (7%), respectively. Median reading time for exams with negative score by all 4 readers (n=20,106) was: Arm A 25 sec, arm B 28 sec, arm C 62 sec (range 36-170), and arm D 58 sec (range 36-156). For the 55 DBT-only detected cancers, median reading time for TP's in arm C-D was 229 and 217 sec compared with 70 and 59 sec for FN's, respectively. 4/6 (67%) of SDC among the 30 discordant DBT-only cancers with less than 45 sec reading time presented as spiculated mass or distortion. The TP rate (detected cancers among all read) for arms C-D for individual readers varied from 7% to 39%. The radiologist with shortest reading time missed most cancers.

**CONCLUSION**
Discordant interpretation is a challenge in screening including use of DBT, and subtle cancers presenting as spiculations might easily be missed at DBT using batch reading

**CLINICAL RELEVANCE/APPLICATION**
Subtle cancers manifesting with spiculations might easily be overlooked. Training and careful reading might reduce number of missed small cancers

**SSA01-02** Breast Density Comparison Between Synthesized Versus Full Field Digital Mammography

Sunday, Nov. 26 10:55AM - 11:05AM Room: Arie Crown Theater

**Participants**
Irfanullah Haider, MD, MBA, SALT LAKE CITY, UT (Presenter) Nothing to Disclose
Matthew B. Morgan, MD, Sandy, UT (Abstract Co-Author) Consultant, Reed Elsevier
Anna K. McGow, MD, MBA, Salt Lake City, UT (Abstract Co-Author) Nothing to Disclose

**Awards**
Student Travel Stipend Award
and categorized by Volpara Density Grade (VDG). We divided our population into three 9-year age groups, 47-55, 56-64 & 65-73 in protocols. Breast density was quantitatively measured using Volpara density software (VolparaSolutions, Edition 5 Wellington, NZ) September 2016. We excluded women at high risk as defined by National Health Service Breast Screening Programme (NHSBSP). We included 70,435 consecutive screening digital mammograms for women age 47-73 performed between March 2013 and September 2016.

**METHOD AND MATERIALS**

This institutional review board approved retrospective multi-reader study evaluated breast density on 200 patients who underwent baseline screening mammogram during which both SM and FFDM were obtained from 6/1/2016 through 11/30/2016. Qualitative breast density was independently assigned by 7 readers (blinded to each other) initially viewing FFDM alone. Then, in a separate session, these readers assigned breast density using synthetic views alone on the same 200 patients and were again blinded to each other’s assignment. Qualitative density assessment was based on Breast Imaging Reporting and Data Systems (BI-RADS) 5th Edition. Generalized linear mixed effects model (GLMEM) was used to evaluate the association of breast density between SM and FFDM taking into account random variation by controlling for age and breast thickness on breast density classification and readers. Odds ratios (ORs) and their 95% confidence intervals (CIs) were then calculated for these variables.

**RESULTS**

The OR for denser breast classification in SM versus FFDM was 0.581 (95% CI: 0.460, 0.733; p-value < 0.0001) demonstrating a statistically significant denser breast assignment on SM compared to FFDM per patient across the readers. Raw data analysis shows 81.8% had no change in density assignment between SM and FFDM, 6.3% were higher density in FFDM though 11.9% had a higher density assigned in SM. The OR for compressed breast thickness was 1.26 (p=0.01) reflecting generally lower density in thicker breasts. The OR for age was 1.47 (p-value < 0.001) reflecting higher density BI-RADS classification in younger women.

**CONCLUSION**

SM is associated with a higher qualitative breast density BI-RADS assessment compared to FFDM resulting in a higher likelihood of assigning a greater density classification in SM compared to FFDM.

**CLINICAL RELEVANCE/APPLICATION**

Synthesized mammography (SM) is increasingly replacing full field digital mammography (FFDM), but its impact on qualitative breast density classification has not been studied. Density assessment is important as it conveys information regarding cancer risk and accuracy of mammography, which may alter decisions about adjunctive imaging, therefore determining whether assessment differs between SM and FFDM is important.

**Honored Educators**

Presenters or authors on this event have been recognized as RSNA Honored Educators for participating in multiple qualifying educational activities. Honored Educators are invested in furthering the profession of radiology by delivering high-quality educational content in their field of study. Learn how you can become an honored educator by visiting the website at: https://www.rsna.org/Honored-Educator-Award/ Maryam Rezvani, MD - 2015 Honored Educator

**SSA01-03 The Relationship between Quantitative Breast Density, Age and Cancer Detection Rate in a Large UK Breast Screening Population**

Sunday, Nov. 26 11:05AM - 11:15AM Room: Arie Crown Theater

**Awards**

**Student Travel Stipend Award**

Participants
Sam Dumontell, MBBS,FRCR, London, United Kingdom (Presenter) Nothing to Disclose
Louise S. Wilkinson, MBChB, FRCR, London, United Kingdom (Abstract Co-Author) Nothing to Disclose
Elizabeth S. Burnside, MD, MPH, Madison, WI (Abstract Co-Author) Nothing to Disclose
Samantha L. Heller, MD, PhD, New York, NY (Abstract Co-Author) Nothing to Disclose
Sue Hudson, London, United Kingdom (Abstract Co-Author) Nothing to Disclose
Shahrooz Mohammadi, MBBS, London, United Kingdom (Abstract Co-Author) Nothing to Disclose

For information about this presentation, contact:
samdumontell@yahoo.co.uk

**PURPOSE**

Quantitative breast density has been proposed as one of the most promising variables to stratify screening strategies; however, little is known about the relationship between density and cancer detection rates (CDR), which we evaluate in a prospectively collected cohort of patients in a UK breast screening program.

**METHOD AND MATERIALS**

We included 70,435 consecutive screening digital mammograms for women age 47-73 performed between March 2013 and September 2016. We excluded women at high risk as defined by National Health Service Breast Screening Programme (NHSBSP) protocols. Breast density was quantitatively measured using Volpara density software (VolparaSolutions, Edition 5 Wellington, NZ) and categorised by Volpara Density Grade (VDG). We divided our population into three 9-year age groups, 47-55, 56-64 & 65-73 in...
order to compare CDR in the lowest (VDG 1) and highest (VDG 4) density women stratified by age. Differences in CDR by density group in each tertile were tested using Fisher’s exact test with p<0.05 to signify statistical significance.

RESULTS
A total of 70,435 screening mammograms in 63,577 women were included revealing 557 cancers for an overall CDR of 0.8%. In 47-55 year olds, women in the VDG 1 density group had a CDR of 0.16%; women in the VDG 4 density group had a CDR of 0.85%. The difference of 0.69% was statistically significant (p=0.01). In 56-64 year olds, women in the VDG 1 density group had a CDR of 0.63%; women in the VDG 4 density group had a CDR of 0.58%. The difference of 0.04% was not statistically significant (p=0.84). In 65-73 year olds, women in the VDG 1 density group had a CDR of 0.99%; women in the VDG 4 density group had a CDR of 0.24%. The difference of 0.75% was statistically significant (p=0.04).

CONCLUSION
We found an opposite trend between breast density and CDR between the youngest and oldest age groups. Older women with the least dense breasts had a higher CDR than those with the densest breasts while the reverse was true in younger women. The differences in CDR between the densest and least dense women were statistically significant in the youngest and oldest age groups.

CLINICAL RELEVANCE/APPLICATION
The relationship between cancer detection rate and density may vary with age and should be taken into account when stratifying women into different screening strategies based on density.

Participants
Yi-Chen Lai, MD, Taipei, Taiwan (Presenter) Nothing to Disclose
Kimberly M. Ray, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Amie Y. Lee, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Jessica H. Hayward, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Rita I. Freimanis, MD, Winston-Salem, NC (Abstract Co-Author) Nothing to Disclose
Bonnie N. Joe, MD, PhD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Iryna Lobach, San Francisco, CA (Abstract Co-Author) Nothing to Disclose

For information about this presentation, contact:
kimberly.ray@ucsf.edu

PURPOSE
To compare the performance of two-dimensional synthetic mammography (SM) in combination with digital breast tomosynthesis (DBT) versus conventional full-field-digital mammography (FFDM) in the detection of microcalcifications on screening examinations.

METHOD AND MATERIALS
In this HIPAA-compliant, IRB-approved protocol, a multi-reader (n=4), retrospective observer study was conducted. Seventy-two consecutive screening mammograms performed with FFDM, digital breast tomosynthesis (DBT), and SM, which were recalled for calcifications from 2014-2015, constituted the study dataset. There were 54 benign and 18 malignant calcification cases. Twenty normal control screening mammograms without calcifications were also included. All normal or benign cases were with verified with at least 1-year follow-up and suspicious lesions verified with biopsy. Two anonymized datasets were created, one consisting of FFDM images and another consisting of SM and DBT images. Two readers reviewed each anonymized dataset. Calcification recalls were tabulated. Sensitivity and specificity for calcification detection were calculated and compared for the SM+DBT versus FFDM group. A mixed effects generalized linear model was used to account for correlation between multiple interpretations of the same image.

RESULTS
Reader agreement for FFDM was 82.6% (95%CI, 73.3%-89.7%), Cohen’s kappa = 0.733, p<0.001 and for SM+DBT was 79.3% (95%CI, 69.6%-89.1%), Cohen’s kappa = 0.677, p<0.001. Overall sensitivities for benign and malignant calcification detection were 77.8% and 94.4%, respectively, for FFDM versus 59.3% and 88.9%, respectively, for SM+DBT. Specificity was 100% for FFDM and 97.5% for SM+DBT. There were no statistically significant differences in either sensitivity or specificity between the study groups (p>0.89).

CONCLUSION
Relative to FFDM, SM in combination with DBT demonstrated a trend towards lower sensitivity for the detection of calcifications on screening examinations, although this did not reach statistical significance. There was no significant difference in specificity between the study groups. Further investigation with a larger dataset is ongoing.

CLINICAL RELEVANCE/APPLICATION
Relative to FFDM, SM in combination with DBT may have reduced sensitivity for the detection of calcifications, and therefore continued acquisition of FFDM images for screening examinations may be warranted.

Participants
Maryam Etesami, MD, New Haven, CT (Presenter) Nothing to Disclose
Michelle Y. Giwerc, New Haven, CT (Abstract Co-Author) Nothing to Disclose
Digital breast tomosynthesis (DBT) is known to increase cancer detection while reducing false positive recalls in screening mammography. However, the impact of additional cancers detected is not well understood. The purpose of this study was to assess detection rate, type, size and axillary lymph node status of cancers detected with DBT compared with digital mammography (DM) alone.

METHOD AND MATERIALS

This was a retrospective institutional review board approved, HIPAA compliant study with waiver of informed consent. DM screening mammograms performed from August 1, 2008 through August 1, 2011 and DBT screening mammograms performed from August 1, 2011 through August 1, 2016 at an academic center were reviewed. DBT screening mammogram was offered to all patients after installation. Cancer detection rates were calculated and compared between the DM and DBT screening mammograms. Histological type of detected cancers, their size, receptor phenotype and lymph node status based on sentinel axillary lymph node biopsy were compared between the 2 groups of DBT and DM only screening.

RESULTS

This study included a total of 44050 screening mammograms, 28282 (64%) DBT and 15768 (36%) DM only. The cancer detection rate was 5.41 per 1000 patients screened with DBT and 4.95 per 1000 patients screened with DM only (p=0.52). There was no significant difference in proportions of in situ and invasive cancers detected (67% and 70% invasive cancers with DBT and DM only, respectively. p=0.55). However, the cancers detected with DBT were significantly smaller (1.54 ± 1.4 cm) compared with cancers detected with DM only (2.30 ± 2.3 cm) (p=0.01). Additionally, axillary lymph node metastasis in invasive cancers was reduced to approximately half with DBT screening (14.7%) compared to DM only screening (30.9%) (p=0.03). DBT screening detected more invasive cancers with lobular histology (13%) compared with DM only (7%), but the difference was not statistically significant (p=0.29). There was no significant difference in receptor phenotype of the cancers detected by DBT compared to DM only screening.

CONCLUSION

DBT screening detects smaller cancers with fewer positive axillary lymph nodes compared to DM. This difference may translate to less systemic treatment and improved clinical outcomes.

CLINICAL RELEVANCE/APPLICATION

DBT screening may improve breast cancer early detection compared to DM which may lead to less systemic treatment and improved clinical outcomes.
CONCLUSION
In female Medicare beneficiaries, screening mammography utilization was associated with higher likelihood of adherence to other preventive guidelines, and without a negative association between false positive results and near-term cervical cancer or osteoporosis screening. Potential effects of mammography on attitudes toward preventive testing merit further investigation.

CLINICAL RELEVANCE/APPLICATION
False positive mammograms do not deter women from undergoing cervical cancer or osteoporosis screening. Screening mammography use was associated with improved subsequent uptake of preventive tests. SSA01-07 Unique Mammographically-Derived Compositional Signatures of Malignancy and Triple-Negative Breast Cancers

Participants
Serghei Malkov, PhD, San Francisco, CA (Presenter) Nothing to Disclose
Roman Camarda, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Andrei Goga, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Bonnie N. Joe, MD, PhD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Jennifer S. Drukeleinis, MD, Tampa, FL (Abstract Co-Author) Nothing to Disclose
Heather I. Greenwood, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Jesus A. Avila, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Bo Fan, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Karen Drukker, PhD, Chicago, IL (Abstract Co-Author) Royalties, Hologic, Inc
Bethany L. Niell, MD, Tampa, FL (Abstract Co-Author) Nothing to Disclose
Leila Kazemi, RT, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Karla Kerlikowske, MD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose
Maryellen L. Giger, PhD, Chicago, IL (Abstract Co-Author) Stockholder, Hologic, Inc; Stockholder, Quantitative Insights, Inc;
Shareholder, QView Medical, Inc; Co-founder, Quantitative Insights, Inc; Royalties, Hologic, Inc; Royalties, General Electric Company; Royalties, MEDIAN Technologies; Royalties, Riverain Technologies, LLC; Royalties, Mitsubishi Corporation; Royalties, Toshiba Medical Systems Corporation
John A. Shepherd, PhD, San Francisco, CA (Abstract Co-Author) Nothing to Disclose

For information about this presentation, contact:
serghei.malkov@ucsf.edu

PURPOSE
To investigate the unique lipid, water, and protein composition of malignant breast cancers by receptor status to non-malignant breast tissue in a cohort of high risk women (BIRADS 4 or greater).

METHOD AND MATERIALS
A dual-energy mammography technique (3CB) was used to quantify lipid, protein, and water composition. The lesion dataset included malignant (invasive and DCIS, N=86) and non-malignant (fibroadenoma and benign, N=282) groups. The malignant group contained 10 triple-negative and 34 receptor-positive invasive cancers. Within regions identified by the radiologists, water, lipid, and protein measures were generated and within three surrounding rings of 2 mm thicknesses. Differences and ratios between lesions and rings were also calculated. Logistic regression with cross validation was applied to analyze lesion type separation.

RESULTS
The most significant variables to discriminate malignancy were lipid differences between lesion and rings (p-value (p)=10E-5, odds ratio (OR)=0.57), protein (water) difference between lesion and rings (p=10E-4, OR=1.66), and ratios of lesion water to rings (p=10E-5, OR=1.79). At the same time, the most significant variables of triple-negative and receptor-positive discrimination were lipid difference (negative) between ring 1 and ring 3 (p=0.03, OR=0.24 (0.065, 0.86)) and the increasing lipid levels (slope) from inner to outer ring (p=0.07, OR=2.44 (0.92, 6.5)). Thus, the lipid content within the lesion relative to the surrounding rings is a marker of malignancy, but the steeper lipid gradient outside of the lesion is a marker of triple-negative breast cancer.

CONCLUSION
We found biologically meaningful water, lipid, and protein compositions of lesion and its periphery that are statistically significant for malignancy/non-malignancy and triple-negative/receptor-positive separation. In addition, future studies will determine if the lipid gradient surrounding the lesion is indicative of active lipolysis within adjacent mammary adipocytes. If true, this advanced mammography imaging technique could aid in selecting patients that benefit from inhibition of this lipolysis.

CLINICAL RELEVANCE/APPLICATION
Advanced dual-energy mammography may reduce unnecessary biopsies and better select women with invasive cancer by receptor status.

SSA01-08 Breast Cancer Detection Rate of Supplemental Screening with Abbreviated MR for Women with Dense Breasts: Preliminary Results

Participants
Susan Weinstein, MD, Philadelphia, PA (Presenter) Consultant, iCAD, Inc
Mitchell D. Schnall, MD, PhD, Philadelphia, PA (Abstract Co-Author) Nothing to Disclose
Elizabeth S. McDonald, MD, Philadelphia, PA (Abstract Co-Author) Nothing to Disclose
Alice Chong, MD, Philadelphia, PA (Abstract Co-Author) Nothing to Disclose
Emily F. Conant, MD, Philadelphia, PA (Abstract Co-Author) Consultant, Hologic, Inc Consultant, Siemens AG

Sunday, Nov. 26 11:45AM - 12:05PM Room: Arie Crown Theater

For information about this presentation, contact:
susan.weinstein@uphs.upenn.edu

PURPOSE
To determine the breast cancer detection rate (BCDR) of supplemental screening with abbreviated MRI (MR) for women with dense breasts.

METHOD AND MATERIALS
A prospective, multi-center, phase II trial of supplemental screening with abbreviated MR for women with dense breasts. Inclusion criteria were women with dense breasts, age 35-95 years, no history of breast cancer, and no contraindication to MR. Abbreviated MR was performed using the Toshiba Multi-Source Dual Energy 320 Multidetector CT System with dedicated breast coils. Imaging parameters included 120 kVp dual-energy acquisitions, 0.4-mm slice thickness, and 20-25s per acquisition. Imaging was interpreted by a blinded radiologist with 10 years of mammography experience. The BCDR was calculated as the percentage of women with new lesions detected by abbreviated MR who underwent further diagnostic workup.

RESULTS
A total of 94 women were enrolled in the study, of whom 45 had new lesions detected on abbreviated MR. Of these, 29 (64.4%) underwent further diagnostic workup. The BCDR of abbreviated MR was 19.1% (17.8% for new lesions and 21.1% for new and interval cancers).

CONCLUSION
The BCDR of supplemental screening with abbreviated MR for women with dense breasts was 19.1%. Further studies are needed to evaluate the clinical impact of abbreviated MR on outcomes such as cancer detection and patient satisfaction.
**PURPOSE**

Dense breast tissue decreases the sensitivity of mammography and many women with dense breasts are requesting supplemental screening such as whole breast ultrasound. At our institution we offer an abbreviated Breast MRI (AB-MR) examination as an option for women seeking supplemental screening. In this study, we evaluate the early outcomes of our AB-MR examination in asymptomatic women with dense breast tissue and negative recent mammography.

**METHOD AND MATERIALS**

An IRB approved and HIPAA compliant retrospective review was performed of women with who underwent supplemental screening with AB-MR examination. All women were asymptomatic. Their most recent mammogram was negative or benign (BI-RADS 1 or 2) and rated as "dense" (heterogeneous or extreme). The cancer detection and false positive rates were calculated based on pathologic correlation.

**RESULTS**

86 women underwent supplemental screening with AB-MR from January 2016 to April 2017. The age ranged from 41 to 76 years, mean 56 years. Four patients (4.6%) were categorized as BI-RADS category 4. Pathology results revealed 1 invasive ductal carcinoma, 1 invasive lobular carcinoma, 1 radial scar, and 1 case of fibrocystic change. The supplemental cancer detection rate with AB-MR was 2/86 or estimated to 23 per thousand with 2 false positive exams.

**CONCLUSION**

Given the additional cancer detection during our early implementation of AB-MR screening, the examination appears very promising as a supplemental screening tool in women with dense breasts. However, more data is needed for validation.

**CLINICAL RELEVANCE/APPLICATION**

Our preliminary results suggest that the AB-MR may have a role as a supplemental screening option for women with dense breast tissue.